Trial reportmSphere2021
Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07221370 (Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07221370 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.JAMA network open · 2023Trial
- Clostridioides difficile colonization amplification despite limited in-hospital transmission: A modeling study.PLoS medicine · 2026Article
- Genome sequencing for prevention of health-care-associated bacterial infections.Nature reviews. Microbiology · 2026Review
- Dietary ellagic acid inhibiting gastrointestinal pathogens by modulation of microbiome-metabolite-immune axis.Natural products and bioprospecting · 2026Article
- Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family.Nature communications · 2025Article
- Observational
- Insights into the Interaction BetweenJournal of personalized medicine · 2025Review
- Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2025Article
- Impact of an Intervention Program onOpen forum infectious diseases · 2024Article
- Decolonization and Pathogen Reduction Approaches to Prevent Antimicrobial Resistance and Healthcare-Associated Infections.Emerging infectious diseases · 2024Review
- Impact of the Reverse 2-Step Algorithm forOpen forum infectious diseases · 2024Article
- Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole inJournal of microbiology and biotechnology · 2024Article
- Management and Outcomes of Patients at a Specialty Clinic forOpen forum infectious diseases · 2024Article
- Genomic surveillance ofmBio · 2024Article
- Informing estimates of probability ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Antibiotic perturbations to the gut microbiome.Nature reviews. Microbiology · 2023Review
- Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Review
- A Vancomycin HPLC Assay for Use in Gut Microbiome Research.Microbiology spectrum · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Skye R S FishbeinThe Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-9554-1170
Tiffany HinkDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Kimberly A ReskeDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Candice CassDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Emily StruttmannDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Zainab Hassan IqbalDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Sondra SeilerDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Jennie H KwonDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
C A BurnhamDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-1137-840X
Gautam DantasThe Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA dantas@wustl.edu edubberk@wustl.edu.ORCID 0000-0003-0455-8370
Erik R DubberkeDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA dantas@wustl.edu edubberk@wustl.edu.
Washington University in St. Louis · US
Funding
Pediatric Gastroenterology Research Training ProgramT32DK077653 · NIDDK · WASHINGTON UNIVERSITY · PI PHILLIP I TARR · 2007 to 2026
$5.8MTunable therapeutic modulation of the gut microbiome by engineered probioticsR01AT009741 · NCCIH · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, MOON, TAE SEOK · 2018 to 2022
$3.5MOccupational Exposure and Health Risk from Dairy Microbiome and Resistome to Dairy Farm WorkersR01OH011578 · OH · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, SHUKLA, SANJAY K · 2018 to 2021
$2.0MPEDIATRIC GASTROENTEROLOGY RESEARCH TRAININGT32HD007409 · NICHD · WASHINGTON UNIVERSITY · PI TARR, PHILLIP I · 1991 to 2005
$978kLongitudinal Analysis of the Fecal Microbiome and Resistome of Patients with Multidrug-Resistant Urinary Tract Infections and Predictors of RecurrenceK23AI137321 · NIAID · WASHINGTON UNIVERSITY · PI KWON, JENNIE H · 2019 to 2022
$675kNCCIH NIH HHS R01 AT009741NIAID NIH HHS K23 AI137321NICHD NIH HHS T32 HD007409NIDDK NIH HHS T32 DK077653NIOSH CDC HHS R01 OH011578
Abstract
PubMed holds no abstract for this paper.
Indexed as
Administration, OralAdultAgedAnti-Bacterial AgentsClostridioides difficileClostridium InfectionsFecesFemaleGastrointestinal MicrobiomeHumansMaleMetagenomicsMiddle AgedVancomycinVancomycin-Resistant EnterococciAnti-Bacterial AgentsVancomycinC. difficilevancomycinvancomycin-resistant enterococci
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07221370ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.